127 related articles for article (PubMed ID: 24908961)
1. [Additional chromosomal abnormalities in dynamic of target therapy for chronic myeloid leukemia in children and adolescents].
Andreeva SV; Drozdova VD
Lik Sprava; 2014; (1-2):55-9. PubMed ID: 24908961
[TBL] [Abstract][Full Text] [Related]
2. Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?
Jabbour E; Cortes J; Kantarjian H
Oncology (Williston Park); 2007 May; 21(6):653-62; discussion 663-4, 667-8. PubMed ID: 17564324
[TBL] [Abstract][Full Text] [Related]
3. Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty.
Giona F; Mariani S; Gnessi L; Moleti ML; Rea M; De Vellis A; Marzella D; Testi AM; Foà R
Haematologica; 2013 Mar; 98(3):e25-7. PubMed ID: 22983586
[No Abstract] [Full Text] [Related]
4. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
5. Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib.
Chahardouli B; Zaker F; Mousavi SA; Saffari Z; Nadali F; Ostadali M; Ghadimi H; Alimoghaddam K; Ghavamzade A; Rostami S
Hematology; 2013 Nov; 18(6):328-33. PubMed ID: 23676790
[TBL] [Abstract][Full Text] [Related]
6. [Trisomy of chromosome 8 in Ph-negative cells of the bone marrow in patients with chronic myeloid leukemia treated with inhibitors of BCR-ABL tyrosine kinases].
Turkina AG; Domracheva EV; Vorontsova AV; Aseeva EA; Vinogradova OIu; Stakhina OV; Gusarova GA; Diagileva OA; Semenova EA; Vakhrusheva MV; Kolosheĭnova TI; Abakumov EM; Chelysheva EIu; Goriacheva SR; Ivanova TV; Zakharova ES; Kolosova LIu; Zakharova AV; Naumova IN; Diachenko LV; Kulikov SM; Kovaleva LG; Khoroshko ND
Ter Arkh; 2009; 81(7):29-36. PubMed ID: 19708570
[TBL] [Abstract][Full Text] [Related]
7. Targeted chronic myeloid leukemia therapy: seeking a cure.
Fausel C
J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):8-12. PubMed ID: 17970609
[TBL] [Abstract][Full Text] [Related]
8. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
[TBL] [Abstract][Full Text] [Related]
9. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Hochhaus A; Kreil S; Corbin AS; La Rosée P; Müller MC; Lahaye T; Hanfstein B; Schoch C; Cross NC; Berger U; Gschaidmeier H; Druker BJ; Hehlmann R
Leukemia; 2002 Nov; 16(11):2190-6. PubMed ID: 12399961
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients.
Joshi D; Chandrakala S; Korgaonkar S; Ghosh K; Vundinti BR
Gene; 2014 Jun; 542(2):109-12. PubMed ID: 24680705
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.
Kolb EA; Pan Q; Ladanyi M; Steinherz PG
Cancer; 2003 Dec; 98(12):2643-50. PubMed ID: 14669284
[TBL] [Abstract][Full Text] [Related]
12. p-Stat3 and bcr/abl gene expression in chronic myeloid leukemia and their relation to imatinib therapy.
Sayed D; Badrawy H; Gaber N; Khalaf MR
Leuk Res; 2014 Feb; 38(2):243-50. PubMed ID: 24374144
[TBL] [Abstract][Full Text] [Related]
13. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance.
Chahardouli B; Zaker F; Mousavi SA; Kazemi A; Ostadali M; Nadali F; Rostami S; Alimoghaddam K; Ghavamzade A
Hematology; 2013 May; 18(3):158-62. PubMed ID: 23540562
[TBL] [Abstract][Full Text] [Related]
15. Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia.
Machaczka M; Gossart M
Pol Arch Med Wewn; 2013; 123(5):251-2. PubMed ID: 23722191
[No Abstract] [Full Text] [Related]
16. A patient of chronic myelogenous leukemia developing painful rash on feet.
Kumar P; Das NK; Sil A; Chakrabarti P
J Postgrad Med; 2012; 58(4):331-4. PubMed ID: 23298941
[No Abstract] [Full Text] [Related]
17. [Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].
Camañas-Troyano C; Calderón-Acedos C; Moriel-Sánchez Mdel C; Segura-Bedmar M
Farm Hosp; 2013; 37(5):428-9. PubMed ID: 24128110
[No Abstract] [Full Text] [Related]
18. Persistence of chromosomal abnormalities additional to the Philadelphia chromosome after Philadelphia chromosome disappearance during imatinib therapy for chronic myeloid leukemia.
Zaccaria A; Valenti AM; Donti E; Gozzetti A; Ronconi S; Spedicato F
Haematologica; 2007 Apr; 92(4):564-5. PubMed ID: 17488671
[TBL] [Abstract][Full Text] [Related]
19. [Research advance on molecular genetics of CML blast crisis].
Zhu HQ; Zhang S; Liu XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
[TBL] [Abstract][Full Text] [Related]
20. Is b3a2 a better prognostic variant in childhood chronic myeloid leukemia?
Malhotra KP; Sharma CB; Jain J; Grover RK
J Postgrad Med; 2010; 56(3):221-2. PubMed ID: 20739774
[No Abstract] [Full Text] [Related]
[Next] [New Search]